| 1. |
岡本勇, ASCO/JSMO Joint Symposium
Combination therapy with molecularly targeted agents in lung cancer
, 第15回日本臨床腫瘍学会学術集会, 2017.07. |
| 2. |
岡本 勇, Recent advances in the treatment of metastatic NSCLC
-Ready for molecular-based treatment-
, 4th Singapore Society of Oncology and Chapter of Medical Oncologist Review, 2012.02. |
| 3. |
Okamoto I., Best of Molecular-Targeted Therapy –ASCO2012-
, Best of ASCO 2012 in Japan, 2012.07. |
| 4. |
Okamoto I., Beyond EGFR-TKI based combination therapy for overcoming acquired resistance
, 4th West Japan Oncology Group International Symposium, 2012.04. |
| 5. |
Okamoto I., Great clinical impact of molecular-targeted therapy against driver
gene alterations in advanced non-small-cell lung cancer (NSCLC)
, 第52回日本呼吸器学会学術講演会 International Symposium, 2012.04. |
| 6. |
Okamoto I., Challenging topics in the development of driver oncogene targeted therapies
, IASLC Local Symposium, 2012.10. |
| 7. |
Okamoto I., Phase II study of oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizuab as first-line therapy for advanced non-squamous non-small-cell lung cancer
, 5th Asian Pacific Lung Cancer Congress(APLCC), 2012.02. |
| 8. |
Okamoto I., Potential combination of EGFR-TKIs and survivin suppressor
For EGFR-mutant advanced non-small-cell lung cancer
, 2nd Japan Taiwan Oncology Phase I Trial Conference (JTOPIC), 2013.03. |
| 9. |
Okamoto I., Non-Small-Cell-Lung Cancer: Molecular target
, Best of ASCO2013 in Japan, 2013.07. |
| 10. |
Okamoto I., ASCO/JSMO joint symposium
Biomarker analyses in clinical trials for NSCLC
~ West Japan Oncology Group (WJOG) perspective ~
, 第11回日本臨床腫瘍学会学術集会, 2013.08. |
| 11. |
Okamoto I., JCA-JSMO Joint Symposium
Clinical challenge for therapy based on the cancer specific genomic alterations in advanced NSCLC
, 第72回日本癌学会学術総会, 2013.10. |
| 12. |
Okamoto I., Multiplexed Genomic Profiling of Non-Small-Cell Lung Cancer(NSCLC)
, 11th International Conference of the Asian Clinical Oncology Society (ACOS), 2014.05. |
| 13. |
岡本 勇, ESMO/JSCO Joint Symposium
A new era of genotype-based targeted therapies for advance non-small-cell lung cancer
, 第52回日本癌治療学会学術集会, 2014.08. |
| 14. |
Okamoto I., Safety Data Analyses For First-Line Pemetrexed Plus Carboplatin in Nonsquamous Non-Small Cell Lung Cancer (ns-NSCLC), European Society of Medical Oncology(ESMO), 2014.09. |
| 15. |
Okamoto I., Safety Data Analyses For First-Line Pemetrexed Plus Carboplatin in Nonsquamous Non-Small Cell Lung Cancer (ns-NSCLC), Chicago Multidisciplinary Symposium in Thoracic Oncology, 2014.10. |
